93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers

ConclusionPatients treated with a heterologous viral vector-based immunotherapy produce remarkable CD8 T-cell responses specific for predicted HLA Class I neoantigens. These results demonstrate proof-of-concept for the immunogenicity of our novel prime/boost approach. Treatment was well tolerated without DLTs. Additional patients and data will be presented.Clinical trial identificationNCT03639714; NCT03953235.Legal entity responsible for the studyGritstone Oncology.FundingGritstone Oncology.DisclosureM.L. Johnson: Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Research grant / Funding (institution), Travel / Accommodation / Expenses: Incyte; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Guardant Health; Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Research grant / Funding (institution): Oncomed; Research grant / Funding (institution): BerGenBio; Research grant / Funding (institution): Lilly; Travel / Accommodation / Expenses: Sysmex; Travel / Accommodation / Expenses: Vapotherm; Research grant / Funding (institution), Travel / Accommodation / ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research